177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: progress of the LEVEL / GETNE-t2217 trial

Jaume Capdevila; Alejandro Garcia-Alvarez; Jorge Hernando; Alice Durand; Urbano Anido; Eric Baudin; Rocio Garcia-Carbonero; Javier Molina-Cerrillo; Olmo-Garcia Maribel del; Paula Jimenez-Fonseca; Catherine Ansquer; Come Lepage; Vinuales Marta Benavent; Ruffinelli Jose Carlos; Amandine Beron; Magalie Haissaguerre; Emmanuel Deshayes; David Taieb; Maddalena Sansovini; Virginia Pubul; Nicola Fazio; Thomas Walter

doi:10.1530/endoabs.110.EP608

Article de revue

177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: progress of the LEVEL / GETNE-t2217 trial

Jaume Capdevila, Alejandro Garcia-Alvarez, Jorge Hernando, Alice Durand, Urbano Anido, Eric Baudin, Rocio Garcia-Carbonero, Javier Molina-Cerrillo, Olmo-Garcia Maribel del, Paula Jimenez-Fonseca, …

Endocrine Abstracts

09/05/2025

DOI: https://doi.org/10.1530/endoabs.110.EP608

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

Détails

Titre: 177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: progress of the LEVEL / GETNE-t2217 trial
Créateurs - sans rôle: Jaume Capdevila
Alejandro Garcia-Alvarez
Jorge Hernando
Alice Durand
Urbano Anido
Eric Baudin
Rocio Garcia-Carbonero
Javier Molina-Cerrillo
Olmo-Garcia Maribel del
Paula Jimenez-Fonseca
Catherine Ansquer
Come Lepage
Vinuales Marta Benavent
Ruffinelli Jose Carlos
Amandine Beron
Magalie Haissaguerre
Emmanuel Deshayes
David Taieb
Maddalena Sansovini
Virginia Pubul
Nicola Fazio
Thomas Walter
Détails de publication: Endocrine Abstracts
Identifiants: 99141272009311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article